Literature DB >> 9010218

Field cancerisation and polyclonal p53 mutation in the upper aero-digestive tract.

F Waridel1, A Estreicher, L Bron, J M Flaman, C Fontolliet, P Monnier, T Frebourg, R Iggo.   

Abstract

Field cancerisation of the aerodigestive tract is caused by chronic exposure to alcohol and tobacco, but the nature of the genetic alterations preceding overt malignancy is unknown. To identify potential field changes we have used a functional assay which tests the transcriptional competence of human p53 expressed in yeast. To increase the sensitivity and reliability of the technique for samples containing under 20% mutant p53, the 5' and 3'-ends of the p53 cDNA were examined separately. With this split form of the assay the tissue p53 mRNA acts as its own control for RNA quality. Mutations were detected in 87% (46/53) of tumours, reflecting the high sensitivity of the technique. Multiple biopsies of histologically normal tissue from the upper aero-digestive tract were tested and clonal p53 mutations were identified in 76% (38/50) of biopsies from patients presenting with multiple tumours compared with 32% (38/117) of biopsies from patients presenting with single tumours (P<0.000001). All patients (16/16) presenting with multiple tumours had at least one positive biopsy, compared with only 53% (19/36) of patients presenting with single tumours (P <0.001). This defines expansion of multiple clones of mutant p53-containing cells as an important biological mechanism of field cancerisation, and provides a means to identify patients likely to benefit from intensive screening for the development of new head and neck tumours.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9010218     DOI: 10.1038/sj.onc.1200812

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  32 in total

1.  Determination of optimal conditions for analysis of p53 status in leukemic cells using functional analysis of separated alleles in yeast.

Authors:  Jana Smardová; Sárka Pavlová; Hana Koukalová
Journal:  Pathol Oncol Res       Date:  2003-02-11       Impact factor: 3.201

2.  Diffusion-weighted MRI in pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer.

Authors:  Raphael Richard; Isabelle Thomassin; Marion Chapellier; Aurélie Scemama; Patricia de Cremoux; Mariana Varna; Sylvie Giacchetti; Marc Espié; Eric de Kerviler; Cedric de Bazelaire
Journal:  Eur Radiol       Date:  2013-05-08       Impact factor: 5.315

3.  TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial.

Authors:  Hervé Bonnefoi; Martine Piccart; Jan Bogaerts; Louis Mauriac; Pierre Fumoleau; Etienne Brain; Thierry Petit; Philippe Rouanet; Jacek Jassem; Emmanuel Blot; Khalil Zaman; Tanja Cufer; Alain Lortholary; Elisabet Lidbrink; Sylvie André; Saskia Litière; Lissandra Dal Lago; Véronique Becette; David A Cameron; Jonas Bergh; Richard Iggo
Journal:  Lancet Oncol       Date:  2011-05-11       Impact factor: 41.316

4.  Screen p53 mutations in hepatocellular carcinoma by FASAY: a novel splicing mutation.

Authors:  Xiao-mo Wu; Jing-geng Fu; Wang-zhong Ge; Jiang-yan Zhu; Jun-yong Wang; Wei Zhang; Wei Qian; Ke-ke Huo
Journal:  J Zhejiang Univ Sci B       Date:  2007-02       Impact factor: 3.066

5.  11q21.1-11q23.3 Is a site of intrinsic genomic instability triggered by irradiation.

Authors:  Nga Du; Pamela M Baker; To Uyen Do; Christine Bien; Carol M Bier-Laning; Sheetal Singh; Shyh-Jen Shih; Manual O Diaz; Andrew T Vaughan
Journal:  Genes Chromosomes Cancer       Date:  2010-09       Impact factor: 5.006

6.  Genetically abnormal clones in histologically normal breast tissue.

Authors:  P S Larson; A de las Morenas; L A Cupples; K Huang; C L Rosenberg
Journal:  Am J Pathol       Date:  1998-06       Impact factor: 4.307

7.  The role of p53 as a surrogate marker for chemotherapeutical responsiveness in ovarian cancer.

Authors:  Dirk O Bauerschlag; Christian Schem; Marion T Weigel; Constantin Von Kaisenberg; Alexander Strauss; Thomas Bauknecht; Nicolai Maass; Ivo Meinhold-Heerlein
Journal:  J Cancer Res Clin Oncol       Date:  2010-01       Impact factor: 4.553

8.  High frequency of temperature-sensitive mutants of p53 in glioblastoma.

Authors:  Jana Smardova; Kvetoslava Liskova; Barbora Ravcukova; Lenka Kubiczkova; Sabina Sevcikova; Jaroslav Michalek; Miluse Svitakova; Vaclav Vybihal; Leos Kren; Jan Smarda
Journal:  Pathol Oncol Res       Date:  2013-03-28       Impact factor: 3.201

9.  p53 Mutation in histologically normal mucosa of the aero-digestive tract is not a marker of increased risk for second primary carcinoma in head and neck cancer patients.

Authors:  Anette Escher; Elsa Piotet; Francois Waridel; Richard Iggo; Philippe Monnier
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-08-08       Impact factor: 2.503

10.  Multiple head and neck tumors frequently originate from a single preneoplastic lesion.

Authors:  Maarten P Tabor; Ruud H Brakenhoff; Henrique J Ruijter-Schippers; Jacqueline E Van Der Wal; Gordon B Snow; C René Leemans; Boudewijn J M Braakhuis
Journal:  Am J Pathol       Date:  2002-09       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.